U.S. FDA declines to approve Blueprint's therapy for type of stomach cancer
The U.S. Food and Drug Administration declined to approve Blueprint Medicines Corp's therapy for previously treated patients with a type of cancer that affects the stomach and small intestine, the drugmaker said on Friday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Gastric (Stomach) Cancer | Health